The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.

Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering further infusions of FVIII ineffective. FVIII inhibitors can also appear in non-hemophilic individuals causing acqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou-Jaoudeh, Melissa, Delignat, Sandrine, Daventure, Victoria, Astermark, Jan, Lévesque, Hervé, Dimitrov, Jordan D, Deligne, Claire, Proulle, Valérie, Lacroix-Desmazes, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Coagulation & its Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153532/
https://www.ncbi.nlm.nih.gov/pubmed/36655430
http://dx.doi.org/10.3324/haematol.2022.281895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153532/
https://www.ncbi.nlm.nih.gov/pubmed/36655430
http://dx.doi.org/10.3324/haematol.2022.281895

Ejemplares similares